Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BPTSY
Biophytis
$0.25
$0.25
$0.00
▼
$2.08
$586K2.461,154 shsN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.09
+49.5%		$0.08
$0.03
▼
$0.13
$1.04M1.5226,706 shs10,365 shs
PainReform Ltd. stock logo
PRFX
PainReform
$0.82
+0.1%		$0.96
$0.81
▼
$7.95
$710K1.08367,289 shs50,335 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.01
+11.1%		$0.02
$0.01
▼
$5.44
$209K0.13238,339 shs1.39 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BPTSY
Biophytis
0.00%0.00%0.00%0.00%-87.50%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
+49.51%-24.00%+15.44%+64.32%+41.61%
PainReform Ltd. stock logo
PRFX
PainReform
+0.10%-6.71%-4.85%-30.61%-87.11%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+11.11%-2.91%-34.64%-84.62%-99.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BPTSY
Biophytis
$0.25
$0.25
$0.00
▼
$2.08
$586K2.461,154 shsN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.09
+49.5%		$0.08
$0.03
▼
$0.13
$1.04M1.5226,706 shs10,365 shs
PainReform Ltd. stock logo
PRFX
PainReform
$0.82
+0.1%		$0.96
$0.81
▼
$7.95
$710K1.08367,289 shs50,335 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.01
+11.1%		$0.02
$0.01
▼
$5.44
$209K0.13238,339 shs1.39 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BPTSY
Biophytis
0.00%0.00%0.00%0.00%-87.50%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
+49.51%-24.00%+15.44%+64.32%+41.61%
PainReform Ltd. stock logo
PRFX
PainReform
+0.10%-6.71%-4.85%-30.61%-87.11%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+11.11%-2.91%-34.64%-84.62%-99.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BPTSY
Biophytis
0.00
N/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
1.00
SellN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PRPH, PRFX, HEPA, and BPTSY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
PainReform Ltd. stock logo
PRFX
PainReform
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BPTSY
Biophytis
N/AN/AN/AN/A($16.18) per shareN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
PainReform Ltd. stock logo
PRFX
PainReform
$20K35.62N/AN/A$23.07 per share0.04
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.04N/AN/A$2.46 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BPTSY
Biophytis
-$18.43MN/AN/AN/AN/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%N/A
PainReform Ltd. stock logo
PRFX
PainReform
-$5.02M-$736.66N/AN/AN/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$2.25N/AN/AN/A-825.01%-482.05%-88.90%11/5/2026 (Estimated)

Latest PRPH, PRFX, HEPA, and BPTSY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/3/2026Q2 2026
PainReform Ltd. stock logo
PRFX
PainReform
N/A-$1.13N/A-$1.1250N/A$0.01 million
8/13/2026Q2 2026
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$200.00-$0.08+$199.92N/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BPTSY
Biophytis
N/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BPTSY
Biophytis
N/A
0.41
N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
PainReform Ltd. stock logo
PRFX
PainReform
N/A
5.07
N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14

Institutional Ownership

CompanyInstitutional Ownership
BPTSY
Biophytis
0.05%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
PainReform Ltd. stock logo
PRFX
PainReform
37.28%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
BPTSY
Biophytis
3.70%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.06%
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BPTSY
Biophytis
302.35 million338,000N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2011.44 million6.63 millionNo Data
PainReform Ltd. stock logo
PRFX
PainReform
7870,000570,000Not Optionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13020.91 million5.44 millionNo Data

Recent News About These Companies

ProPhase Labs (NASDAQ:PRPH) Stock Breaks Below 200 Day Moving Average - Here's What Happened
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098395
Aurora Cannabis (NASDAQ:ACB) & ProPhase Labs (NASDAQ:PRPH) Financial Comparison
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095605
ProPhase Labs stock reports a 29.4 percent revenue decline
October 1, 2026  |  ad-hoc-news.deA
ProPhase Labs stock holds as latest figures shape the risk profile
September 22, 2026  |  ad-hoc-news.deA
ProPhase Labs Delays Quarterly SEC Filing
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-sec-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Inc.
July 16, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/prph/financials/cash-flow
ProPhase Labs Announces Immediate Resignation of Board Member
June 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PRPH/pressreleases/36984840/prophase-labs-announces-immediate-resignation-of-board-member/
ProPhase Labs Delays Quarterly Financial Filing
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-financial-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
April 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/15/3274530/0/en/prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-and-investment-ready-crown-medical-collections-platform.html
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
March 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/prophase-labs-provides-business-highlighting-120000129.html
ProPhase Labs Explores Strategic Options for BE-Smart Test
February 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-explores-strategic-options-for-be-smart-test?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs, Inc.: ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart and Advances Crown Medical Collections Initiative
February 3, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67599969-prophase-labs-inc-prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart-and-advances-crown-medical-collections-initiative-399.htm
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
February 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/prophase-labs-initiates-potential-sale-120000291.html
ProPhase Labs initiates potential sale or strategic partnership of BE-Smart
February 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4546120-prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
February 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/join-prophase-labs-exclusive-live-investor-webinar-and-q-a-session-on-february-3rd-1035773219
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
January 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prophase-labs-provides-crown-medical-collections-update-250-insurance-payors-engaged-approximately-50-matters-in-advanced-settlement-posture-1035745250
ProPhase Labs Secures Flexible $10 Million Equity Facility
January 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-secures-flexible-10-million-equity-facility?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Uplists from Pink Sheets to OTC Market
January 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prophase-labs-uplists-from-pink-sheets-to-otc-market-1035736260
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
January 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/05/3212517/0/en/prophase-labs-provides-update-on-convertible-debt-conversions-capital-structure-and-underlying-asset-value.html
ProPhase Labs faces NASDAQ delisting, plans appeal, OTC move
January 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/prophase-labs-faces-nasdaq-delisting-plans-appeal-otc-move/ar-AA1TtNWj

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biophytis NASDAQ:BPTSY

$0.25 0.00 (0.00%)
As of 10/13/2026

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.09 +0.03 (+49.51%)
As of 10/14/2026 01:53 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

PainReform stock logo

PainReform NASDAQ:PRFX

$0.82 +0.00 (+0.10%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$0.81 0.00 (-0.59%)
As of 10/14/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.01 +0.00 (+11.11%)
As of 10/14/2026 03:56 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas